Terms: = Kidney tumors AND LEF1, TCF1ALPHA, 51176, ENSG00000138795, Q9UJU2, DKFZp586H0919 AND Treatment
4 results:
1. Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
Keutgen XM; Kumar S; Gara SK; Boufraqech M; Agarwal S; Hruban RH; Nilubol N; Quezado M; Finney R; Cam M; Kebebew E
Cancer; 2018 Feb; 124(3):636-647. PubMed ID: 29149451
[TBL] [Abstract] [Full Text] [Related]
2. Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.
Karim S; Al-Maghrabi JA; Farsi HM; Al-Sayyad AJ; Schulten HJ; Buhmeida A; Mirza Z; Al-Boogmi AA; Ashgan FT; Shabaad MM; NourEldin HF; Al-Ghamdi KB; Abuzenadah A; Chaudhary AG; Al-Qahtani MH
BMC Cancer; 2016 Sep; 16(Suppl 2):741. PubMed ID: 27766950
[TBL] [Abstract] [Full Text] [Related]
3. Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.
Han T; Shang D; Xu X; Tian Y
World J Surg Oncol; 2012 Sep; 10():183. PubMed ID: 22950635
[TBL] [Abstract] [Full Text] [Related]
4. 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing lef1/phospho-β-catenin expression.
Shang D; Liu Y; Xu X; Han T; Tian Y
Cancer Lett; 2011 Dec; 311(2):230-6. PubMed ID: 21880414
[TBL] [Abstract] [Full Text] [Related]
